Company news: Emyria; Ananda Wellness; InhaleRx; Cann Global; HFA by Steve Jones September 28, 2022April 29, 2024 Emyria Nine sites across four states will conduct the phase III clinical trial for Emyria’s EMD-RX5 […]
Ecofibre launches low-cost CBD product and pins hope on OTC market to drive profitability by Steve Jones August 23, 2022April 29, 2024
Over-the-counter sales to create ‘most significant opportunity in years’ says Ecofibre boss by Steve Jones August 3, 2022April 29, 2024
Bod’s S3 registration candidate to go on sale through Special Access Scheme by Steve Jones June 27, 2022April 29, 2024
Over-the-counter race hots up as Cann Group prepares to recruit patients for sleep disturbance trial by Steve Jones February 16, 2022April 29, 2024
Medlab signs deal to promote Cann Group’s Satipharm product to doctors by Steve Jones February 1, 2022April 29, 2024
Althea bets on dual strategy as CEO predicts big pharma will come knocking ‘sooner than we thought’ by Steve Jones September 23, 2021April 26, 2024
Cann Group COO: ‘we need to put our big boy pants on and adopt a pharmaceutical mindset’ by Steve Jones February 25, 2021April 26, 2024
Major doubts remain as industry reacts to CBD down scheduling by Steve Jones September 10, 2020April 22, 2024